Table 1.
Ref. | Regimen | No. patients | Stage | R0 resection (%) | Median survival (mo) |
Wilkie et al[8] | EAP | 34 | NR | 44 | 24 |
Plukker et al[9] | 5-FU + MTX | 20 | NR | 40 | 22 |
Rougier et al[10] | 5-FU, P | 30 | NR | 60 | 16 |
Kelsen et al[11] | FAMTX, IP 5FU-P | 56 | NR | 61 | 15 |
Melcher et al[12] | ECF | 27 | R-NR | 58 (R pts) 10 (NR pts) | 10 |
Gallardo-Rincón et al[13] | P-ELF | 60 | NR | 8,7 | 10 |
Cascinu et al[14] | EAFPLG | 82 | NR | 45 | 17 |
NR: Non-resectable; EAP: Etoposide, doxorubicin, cisplatin; IP: Intraperitoneal; ECF: Epirubicin, cisplatin, 5-FU; R: Resectable; P-ELF: Cisplatin, etoposide, leucovorin, 5FU; EAPFLG: Epi-doxorubicin, 5-FU, cisplatin, leucovorin, glutathione; 5-FU: 5-fluorouracil.